Abstract: A tooth paste composition comprising black cumin oil (Nigella sativa) and fluoride-doped bioactive glass, zinc oxide, and/or titanium oxide is disclosed.

Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.

Abstract: Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

Abstract: A 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Oral care compositions and/or unit-dose oral care compositions comprising a high level of surfactant. Oral care compositions and/or unit-dose oral care compositions with a high foaming efficiency. Oral care compositions and/or unit-dose oral care compositions with one or more web forming materials, one or more surfactants, and a sugar alcohol.

Abstract: Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Abstract: The present invention refers to a set for the production of a ready-to-use chemo-therapeutic composition for intraperitoneal administration as an aerosol, wherein the set comprises an aqueous concentrate containing at least cisplatin in a first predetermined concentration and doxorubicin in a second predetermined concentration with a predetermined ratio of the first and the second concentration and having a pH value in the range from 3.0 to 7.0. The set further comprises a physiological aqueous carrier solution, which is for optional dilution of the concentrate depending on target concentrations of cisplatin and doxorubicin in the chemo-therapeutic composition to be applied. Further, the invention refers to a method for providing of a ready-for-use chemotherapeutic composition for intraperitoneal administration as an aerosol by using of a set, to a chemotherapeutic composition for intraperitoneal administration as an aerosol, and a use of the chemotherapeutic composition.

Abstract: In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

Abstract: Pharmaceutical compositions and methods of treatment or prevention of diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulation of the nitric oxide synthase pathway are provided, as are animal models and drug screening methods. Such modulation may be achieved by the administration of tetrahydrobiopterin (BH4) or its prodrugs and/or salts. Treating and preventing xerostomia can have the downstream effect of also preventing periodontitis, dental caries, parotid gland enlargement, inflammation and fissuring of the lips (chelitis), inflammation or ulcers of the tongue and buccal mucosa, oral candidiasis, salivary gland infection (sialadenitis), halitosis, and cracking and fissuring of oral mucosa.

Abstract: The disclosure herein relates to the innovative epinephrine formulations in aqueous solution of medicinal products that enhance the physicochemical stabilities of epinephrine and extend the product shelf life. In some instances, the formulations comprise epinephrine or a salt thereof, a complexing agent, and a “non-sulfite” antioxidant. The epinephrine formulations substantially demonstrated the superior physicochemical stabilities to conventional sulfite formulation of commercial medications currently available. In some instances, sulfite-free formulations further provide further benefit (e.g., safety benefits) to sulfite-sensitive patients. The compositions, methods for preparing the formulations, and methods of using the same (e.g., in the treatment of anaphylaxis) are also provided.

Abstract: A liposome vesicle comprising a membrane consisting of 1,3-diheptadecanamidopropan-2-yl(2-(trimethylammonio)ethyl)phosphate surrounding a volume comprising a pharmaceutical drug or contrast agent. The vesicle is mechanosensitive at body temperature and at physiologically or pathophysiologically relevant shear stress.

Abstract: Scaffolds for use in bone tissue engineering include a skeleton and a host component. Methods of preparation of scaffolds include identification of biodegradation properties for the skeleton and the host component. The skeleton is constructed to form a three-dimensional shape. The skeleton is constructed of a first material and has a first rate of biodegradation. The host component fills the three-dimensional shape formed by the skeleton. The host component is constructed of a second material and has a second rate of biodegradation. The first rate of biodegradation is slower than the second rate of biodegradation.

Abstract: The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with a 0.

Abstract: Leave-on oral care compositions comprising a hyaluronic acid, and a gum-strengthening polyol are provided for promoting Gum Health of a user.

Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.

Abstract: A method of treating or alleviating symptoms of disease, disorder or condition associated body wasting in a subject, including disease, disorder or condition associated body wasting in the subject, the disorder or condition identified based on initial measures of body mass, body mass index, or a bloodstream concentration of a substance, orally administering to said subject an amount of curcumin over a period of time effective treat or alleviate the disease, disorder or condition associated body wasting, diminishing or reversing the body wasting in the subject, and assessing efficacy of treating or alleviating symptoms of the disease, disorder or condition associated with body wasting by comparing final measures of body mass, body mass index, or a bloodstream concentration of a substance after the treatment period time to the initial measures of body mass, body mass index, or bloodstream concentration of the substance.

Abstract: Termite resistant wood preservative compositions for treating lumber products to control insects are disclosed, consisting of cold pressed orange oil with high concentration D-Limonene and acrylic lacquer for protective repellents against termite infestation, are provided. The preferred termite resistant wood preservative compositions further consist of cold pressed orange oil with a high concentration D-Limonene of at least 80%, an acrylic lacquer, boric acid, and water.

Abstract: Termicidal compositions to control insects consisting of cold pressed orange oil with a high concentration D-Limonene of at least 80% and consisting of an acrylic lacquer, for protective repellents against termite infestation, are provided. The preferred termicidal compositions to control insects consist of cold pressed orange oil with a high concentration D-Limonene of at least 80%, an acrylic lacquer, boric acid, and water.

Abstract: The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

Abstract: Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.